Business
Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook
Total Revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt refinancing 2026 to be a potentially transformational year with Phase 3 Lyme disease data expected in the first half of the yearChief Executive Officer’s contract renewed for a further three-year term, ensuring continuity in leadership Lyon (France), February 19, 2026 – Valneva SE (Nasdaq:
About this update from Valneva Se
[{"type":"image","alt":"VALNEVA","displaySize":"","headline":null,"caption":"VALNEVA","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":44,"url":"https://media.zenfs.com/en/globenewswire.com/29df7eb71c048b91fe66a95a1cd8b1d6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9l2h5dKc1PlSY26lXUAWsA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/29df7eb71c048b91fe66a95a1cd8b1d6","width":300,"height":44}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Total Revenues of €174.7 million in line with guidance, including €157.9 million in product sales ","length":97,"tagName":"p"}]},{"val":[{"type":"text","content":"Strong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt refinancing ","length":122,"tagName":"p"}]},{"val":[{"type":"text","content":"2026 to be a potentially transformational year with Phase 3 Lyme disease data expected in the first half of the year","length":116,"tagName":"p"}]},{"val":[{"type":"text","content":"Chief Executive Officer’s contract renewed for a further three-year term, ensuring continuity in leadership","length":107,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":442,"olType":false},{"type":"text","content":"Lyon (France), February 19, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today reported its preliminary unaudited full-year 2025 revenue and cash results1 and provided a first outlook for 2026.","length":231,"tagName":"p"},{"type":"text","content":"2025 full-year revenue and cash results (unaudited):","length":52,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total revenues of €174.7 million in 2025 compared to €169.6 million in 2024 including recognition of variable consideration relating to the research collaboration and licensing agreement for the Lyme disease program","length":215,"tagName":"p"}]},{"val":[{"type":"text","content":"Product sales of €157.9 million compared to €163.3 million in 2024, as third-party sales decreased by 42.3% to €19.2 million (€33.2 million in 2024), as expected","length":161,"tagName":"p"}]},{"val":[{"type":"text","content":"Product sales increased by 9% at constant exchange rate (CER)2) and excluding third-party sales","length":95,"tagName":"p"}]},{"val":[{"...